Last week, we reported Celltrion's U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar of Janssen's STELARA® (ustekinumab). According to Celltrion, STEQEYMA® is being sold at a wholesale acquisition cost (WAC) list price at an 85% discount to the current WAC list price of STELARA®. This week, Celltrion announced that STEQEYMA® will be sold at Costco pharmacies across the United States under a new listing agreement with Costco Health Solutions, the pharmacy benefit manager arm of Costco. As part of the agreement, STEQEYMA® has been designated a preferred drug and STELARA® will be removed from Costco's formulary. Celltrion USA's Chief Commercial Officer, Thomas Nusbickel, indicated that the company is also finalizing listing agreements with other large pharmacy benefit managers.
The post Celltrion Wins Costco Formulary Listing for its Recently Launched Ustekinumab appeared first on Big Molecule Watch.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
